No Data
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 38% Share Price Surge Not Quite Adding Up
Olin Biotech: Chengdu Olin Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
Chengdu Olin Biotechnology Co., Ltd. 2024 Annual Results Express Announcement
Olin Biotechnology (688319.SH): Net income for the 2024 fiscal year is 19.5751 million yuan, an increase of 11.50% year-on-year.
On February 27, Glonghui reported that Olin Biotech (688319.SH) announced its performance report for the 2024 fiscal year. During the reporting period, the company achieved revenue of 588.8585 million yuan, which is an increase of 18.69% year-on-year; net income attributable to the parent company's owners reached 19.5751 million yuan, up by 11.50% year-on-year; and net income attributable to the parent company's owners, excluding non-recurring gains and losses, was 9.9984 million yuan, representing a significant increase of 195.11% year-on-year. During the reporting period, the company continued to strengthen market promotion, and sales of the tetanus vaccine achieved steady growth.
Chengdu Olymvax Biopharmaceuticals Starts Phase One Clinical Trials for Vaccines
Olin Bio (688319.SH): A trivalent and quadrivalent influenza virus split vaccine (MDCK cells) has initiated Phase I clinical trials and completed the enrollment of the first subject.
On February 21, Gonglonghui reported that Olin Biotech (688319.SH) announced the official launch of Phase I clinical trials for the trivalent influenza virus split vaccine (MDCK cells) and the quadrivalent influenza virus split vaccine (MDCK cells), and completed the enrollment of the first subject. The company's trivalent influenza virus split vaccine (MDCK cells) and quadrivalent influenza virus split vaccine (MDCK cells) are suitable for individuals aged 6 months and older. After vaccination with the influenza vaccine, it can stimulate the body to produce immunity against the influenza virus, aimed at preventing the influenza caused by vaccine-related strains. The company's influenza vaccine is cell-based.
Declining Stock and Decent Financials: Is The Market Wrong About Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319)?
